Loading…
Chronic Kidney Disease Improvement in Research and Treatment Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Chronic Kidney Disease Improvement in Research and Treatment Act This bill expands, establishes, and otherwise modifies requirements under Medicare and other health care programs relating to individuals with end-stage renal disease (ESRD). Among other things, the bill expands the scope of the National Health Service Corps to specifically include kidney disease specialists, modifies payments under the Medicare ESRD program to exclude certain adjustment factors (e.g., comorbidities), authorizes incentive payments for renal dialysis facilities that exceed performance standards under the Medicare ESRD program, and expands guaranteed issue rights with respect to Medigap policies (Medicare supplemental health insurance policies) to all ESRD beneficiaries.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
2020 · fourth_quarter · Medicare/Medicaid
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Health Issues
H.R. 8254/S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to chronic kidney disease (CKD) and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912/S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Emergency response related to COVID-19 H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133, Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · fourth_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: $8,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 133, Consolidated Appropriations Act of 2021 H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 5534/S3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $310,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R. 6800, The Heroes Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020; Extension of the Medicare Sequester
Client expense: Not reported · Firm income: $50,000
2020 · fourth_quarter · Health Issues
Provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment, including the ESRD Prospective Payment System Regulation and S. 1676 /H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · fourth_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19 H.R. 5534/S. 3353 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133 Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,080,000 · Firm income: Not reported
2020 · fourth_quarter · Medicare/Medicaid
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19 H.R. 5534/S. 3353 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020 H.R. 133 Consolidated Appropriations Act, 2021, dialysis and kidney care issues
Client expense: $1,080,000 · Firm income: Not reported
2020 · fourth_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: $14,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R. 6800, The Heroes Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client expense: Not reported · Firm income: $50,000
2020 · third_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912/S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 8177, Renal Anemia Innovation Support and Expansion (RAISE) Act; H.R. 8181, Jack Reynold's Memory MediGap Expansion; Coronavirus Aid Relief, and Economic Security (CARES) Act (P.L. 116-146).
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · third_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
Provide guidance and strategic counsel on federal regulatory policy and legislative issues affecting the quality of kidney care and treatment, including the ESRD Prospective Payment System Regulation and S. 1676 /H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act
Client expense: Not reported · Firm income: $80,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · second_quarter · Health Issues
Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,750,000 · Firm income: Not reported
2020 · second_quarter · Medicare/Medicaid
Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $1,750,000 · Firm income: Not reported
2020 · third_quarter · Medicare/Medicaid
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $860,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Health Issues
H.R. 8254 / S. 4574, Bringing Enhanced Treatments and Therapies to ESRD Recipients (BETTER) Kidney Care Act, all provisions CMS regulations pertaining to reimbursement rates for ESRD-related services CMS regulations pertaining to the Medicare Advantage program Protection of third party premium assistance for coverage under the Patient Protection and Affordable Care Act Issues related to Chronic Kidney Disease and prevention Issues related to home dialysis Issues related to access to kidney transplantation for ESRD patients H.R. 3912 / S.1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019, all provisions ESRD Treatment Choices (ETC) Mandatory Demonstration Worked with HHS and CMS on emergency response related to COVID-19
Client expense: $860,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
2020 · third_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L.116-123); H.R.6201, Families First Coronavirus Response Act (P.L.116-127); H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: Not reported · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act S. 3353 and HR 5534 -- The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; Medicare kidney disease education benefit; End Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019); COVID emergency supplemental, CKD/ESRD issues; Continued monitoring of implementation of Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; Continued monitoring of implementation of Public Law 116-127, Families First Coronavirus Response Act; Continued monitoring of implementation of Public Law 116-136, CARES Act - proposals related to physician and provider relief; H.R, 6800, HEROES Act (including Medicare Accelerated Payment program, increased FMAP payments, COBRA coverage, increased funding for HHS Provider Fund, changes to the Paycheck Protection Program, medical liability reform); Monitor Contract Year 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program Final Rule; H.R. 5534, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S. 3353, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client expense: Not reported · Firm income: $50,000
2020 · second_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescriptioon Drug Benefit Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2021 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; CY 2021 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Program, and Medicare Cost Plan Program rule; H.R. 748, The Coronovirus Aid, Relief, and Economic Security (CARES) Act
Client expense: $510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2020 · second_quarter · Medicare/Medicaid
Medicare coverage and reimbursement for kidney care services including the ESRD Treatment Choices model, telehealth, surprise medical billing, and COVID-19 response; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act (P.L.116-136); H.R.6800, The HEROES Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: $14,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medical/Disease Research/Clinical Labs
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019 S. 3548 -- CARES Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model; H.R.5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; End Stag Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019); Appropriations for KidneyX; COVID emergency supplemental, CKD/ESRD issues; H.R. 6074 (Public Law 116-123), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R. 6201 (Public Law 116-127), Families First Coronavirus Response Act; H.R. 748 (Public Law 116-136), CARES Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Budget/Appropriations
H.R.3912, S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act; FY 21 Labor, Health & Human Services Appropriations including Title VIII Nursing programs; H.R.5575 - Primary and Behavioral Health Care Access Act of 2020.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES
2019 · fourth_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: $10,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2019 · fourth_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: $300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2019 · fourth_quarter · Medical/Disease Research/Clinical Labs
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Medicare/Medicaid
Issues relating to End Stage Renal Disease (ESRD) and Chronic Kidney Disease (CKD); S. 1676 / H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; End-Stage Renal Disease (ESRD) payment reform and quality metrics; End Stag Renal Disease (ESRD) Treatment Choices Model (ETC Model) Proposed Rule (84 FR 34478, 7/18/19); Executive Order on Advancing American Kidney Health (July 10, 2019)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Budget/Appropriations
H.R.3912, S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act; FY 20 Labor, Health & Human Services appropriations related to National Institutes of Health and Agency for Healthcare Research and Quality funding.
Client expense: Not reported · Firm income: $20,000
2019 · third_quarter · Medicare/Medicaid
Issues Related to Medicare's ESRD Program S.511/H.R. 1224, Living Organ Donation Legislation S. 678/H.R. 3912 CKD Improvement Act Issues Related to Vascular Access Care for Kidney Patients Immunosuppressive Drug Coverage for Post-Kidney Transplant Patients
Client expense: $7,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Health Issues
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ERSD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019; H.R. 3436, Seniors' Chronic Care Management Improvements Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Medicare/Medicaid
Issues related to Medicare reimbursement for Part D drugs; Issues related to CY2020 End Stage Renal Disease (ESRD) Prospective Payment System; Medigap insurance access for ESRD beneficiaries; S. 1676, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019;H.R. 3436, Senior's Chronic Care Management Improvement Act of 2019; H.R. 3912, Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: $420,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model; S.1676/H.R.3912, Chronic Kidney Disease Improvement in Research and Treatment Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Budget/Appropriations
H.R.3912, S. 1676 - Chronic Kidney Disease Improvement in Research and Treatment Act; Executive order on the Advancing American Kidney health initiative.
Client expense: Not reported · Firm income: $20,000
2019 · third_quarter · Medical/Disease Research/Clinical Labs
H.R.1224 and S.511, The Living Donor Protection Act S.1676 and H.R.3912 -- The Chronic Kidney Disease Improvement in Research and Treatment Act of 2019
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Medicare/Medicaid
Issues relating to Medicare coverage and reimbursement for kidney care services, including the ESRD Treatment Choices model. S 1676, HR 3912.
Client expense: Not reported · Firm income: Not reported
| Democratic |
| NY |
| Vern Buchanan | Republican | FL |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, SENATE